Winston Francois runs PR for biotech and pharma companies where a press release can move a stock, trigger an off-label review, or get cited in a 10-K. We build the release, the spokesperson prep, and the crisis plan with your legal, medical affairs, and IR teams already in the room, not after the draft leaks.
The Problem
Trial Readout Press Timing Is a Reg FD Problem Disguised as a Marketing Task
A press release announcing topline data is material nonpublic information the moment the biostatistics team unblinds it, and Reg FD sets a real clock on how it gets disclosed. Marketing and comms teams used to consumer product launches default to embargo windows and press-day thinking that simply do not apply when a release has to go out via 8-K or press release plus IR wire simultaneously with no early access to sell-side analysts.
PR Drafts a Release, Legal Kills It, and Nobody Told Marketing Why
A press release that describes a drug's benefit in language even slightly ahead of its approved label reads as off-label promotion to the FDA, and Legal and Regulatory Affairs know this even when the PR team drafting the release does not. Without medical affairs and regulatory in the room from the first draft, comms teams write copy that gets bounced back three or four rounds deep, burning the very news cycle the release was timed around. The company ends up publishing a watered-down release two days late instead of a sharp one on time.
A Trial Hold or Adverse Event Report Hits and There Is No Plan, Just a Group Chat
A clinical hold notice, a serious adverse event disclosure, or an FDA complete response letter creates a 24-to-48 hour window where reporters, analysts, and patients are all asking questions at once, and most biotech companies at this stage have no pre-drafted holding statement, no cleared spokesperson, and no agreed chain of sign-off. Comms ends up improvising language live with legal on the phone, and the first public statement is usually either too vague to be credible or specific enough to create new liability. The gap between the news breaking and the company's first coherent response becomes the story itself.
Trade Press and Consumer Health Press Need Two Different Companies to Show Up
Endpoints News, STAT, and Fierce Biotech want mechanism of action, trial design specifics, and a scientifically literate spokesperson who can survive a follow-up question about the p-value, while a consumer health outlet wants a patient story and a plain-English explanation of what the drug does. Companies that only build one pitch, usually the trade-press version, get ignored by consumer press for launch coverage, and companies that only build the consumer version get torn apart by trade reporters who know the science. Neither audience forgives being pitched the other one's story.
Embargo Coordination Around a Conference Abstract and a Journal Publication Is Two Different Clocks Running at Once
A pivotal trial result often has an abstract embargo tied to ASCO, ASH, or JPM Healthcare Conference release rules on one clock, and a separate, usually longer, embargo tied to the peer-reviewed journal publishing the full data on a different clock, and the two rarely align cleanly. A comms team that treats these as one embargo either breaks the conference society's rules, which can get a company's future abstracts flagged, or breaks the journal's embargo, which can get the paper pulled entirely.
How We Help
We start by mapping who actually has to sign off on external language before it goes anywhere: legal, regulatory affairs, medical affairs, and IR, in that rough order of veto power.
From there we build a message architecture, not a one-off press release template.
On execution, we draft and route releases through your actual approval chain, not around it.
We build two separate pitch narratives for every major announcement: one scientifically precise version for trade and scientific press that can survive a mechanism-of-action question, and one accessible version for consumer health press built around what the result means for patients.
For embargo management, we build a single calendar that tracks the conference abstract embargo, the journal publication embargo, and the Reg FD disclosure window against each other, so nobody discovers a conflict the week of ASCO.
We also run spokesperson prep specific to scientific accuracy, not generic media training.
What we deliver
- Sign-off architecture mapping legal, regulatory, medical affairs, and IR approval chains by release type
- Pre-cleared holding-statement library for adverse events, trial holds, and CRLs
- Reg FD-aligned disclosure timeline template for trial readouts and material announcements
- Dual-track pitch narratives built separately for trade/scientific press and consumer health press
- Master embargo calendar reconciling conference abstract rules, journal publication dates, and disclosure windows
- Spokesperson prep and mock interviews built around real trade-press question patterns
- Post-announcement media monitoring and analyst reaction tracking
The biotech companies that get burned by PR almost never have a writing problem. They have a sequencing problem, where the release ships before legal, medical affairs, and IR agree on what it is allowed to say.
Our Methodology
We run in 90-day sprints because biotech news cycles do not wait for a slower process, but a sign-off system built in a week falls apart the first time it is tested against a real trial readout. Days 1-15 are the sign-off and message-architecture audit: who currently approves what, where releases get stuck, and what the pre-cleared holding statements need to cover. Days 16-45 are build: the message architecture, the embargo calendar, the dual-track pitch narratives, and the spokesperson prep materials, tested against a real upcoming announcement rather than a hypothetical one. Days 46-75 are live execution, running your next actual release or trial readout through the new process with us embedded alongside legal, medical affairs, and IR. Days 76-90 are handoff and refinement, tightening whatever broke during the live test and documenting the process for your internal team to run without us in the room.
This is different from a traditional PR agency retainer in one specific way: we do not treat legal, medical affairs, and regulatory as obstacles to route around, we build the process assuming they are permanent participants, because in this industry they are. An agency that writes a great release and then loses three weeks to compliance review has not actually delivered PR, it has delivered a draft. We measure success by how fast a cleared release ships, not how polished the first draft reads before anyone with veto power sees it.
How We Work
The first 30 days are diagnostic and embedded. We sit in on your legal, medical affairs, and IR review meetings, trace exactly where past releases got stuck or delayed, and build the sign-off architecture and holding-statement library against real historical examples, not hypotheticals.
Days 31-60 are build and live test. We draft your next actual release, trial readout communication, or conference abstract coordination through the new process, working alongside your internal comms, legal, and medical affairs teams rather than handing off a template and waiting for feedback. Weekly working sessions replace one-way status updates, because a stuck approval chain does not get fixed by a status report.
By day 90 you have a working sign-off system, a tested embargo calendar, and spokespeople who have run mock interviews against real trade-press question patterns. From there we typically stay on as fractional PR support, cadence set by your announcement calendar – weekly during an active trial readout or conference season, biweekly or on-call during quieter stretches.
If your biotech or pharma company has a trial readout, conference presentation, or crisis scenario coming up and no tested process for it, we should talk.
- Faster release approval cycles through legal, medical affairs, and IR
- Reduced off-label promotion risk in external-facing language
- Coordinated embargo compliance across conference, journal, and disclosure timelines
- Pre-built crisis response capability for adverse events and trial holds
- Separate credible narratives for trade/scientific press and consumer health press
- Spokespeople prepared for scientifically literate follow-up questions
If your biotech & pharma company needs public relations leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How do you handle Reg FD requirements when a press release involves clinical trial data?
We build the release, the IR disclosure documents, and the reporter briefing materials on the same timeline as your Reg FD obligations, coordinated directly with your IR and legal teams rather than treated as a separate marketing task. That usually means aligning the press release with an 8-K filing or simultaneous wire distribution so no analyst or reporter gets material information ahead of the broader market.
Can you help make sure our press releases do not create off-label promotion risk?
Yes, this is one of the core problems we solve. We build a message architecture that stays inside your currently approved label language and route every release through medical affairs and regulatory before it goes external, which prevents the multi-round rejection cycle that usually delays releases.
What happens if we get a trial hold notice or an adverse event report and need to respond fast?
We build pre-cleared holding-statement language for exactly these scenarios before they happen, so the first public response does not get improvised live with legal on the phone. When an actual event occurs, we help finalize and route the specific statement fast because the sign-off chain and baseline language already exist.
How do you manage embargoes around conference abstracts like ASCO and journal publications at the same time?
We build a single calendar that tracks the conference society's abstract embargo rules, the journal's publication embargo, and any Reg FD disclosure window against each other, then coordinate directly with the journal's press office and the conference media relations team on exact timing. Treating these as separate, unrelated deadlines is how companies accidentally break a rule and get flagged for future submissions.
Do you write differently for trade and scientific press versus consumer health press?
Yes, we build two separate pitch narratives for major announcements rather than one release with adjectives adjusted. Trade and scientific reporters need mechanism of action, trial design detail, and a spokesperson who can handle a technical follow-up question, while consumer health press needs a patient-relevant explanation of what the result means.
What does a public relations engagement cost for a biotech or pharma company at our stage?
Engagements are scoped fractional, typically in the range of $12K-$30K per month depending on announcement volume, whether you have an upcoming trial readout or conference season, and how much spokesperson prep and crisis planning is involved. That covers the embedded team and process build, not a fixed number of releases, because the highest-value early work is usually the sign-off architecture and holding-statement library.
Should legal, medical affairs, and regulatory be involved from the start of a PR engagement?
Yes, and we build the entire process assuming they are permanent participants rather than obstacles. A press release built without medical affairs and legal in the room from the first draft is a release that gets bounced back multiple rounds and often ships late or diluted.
